Prospective randomized open-label comparative study of immunogenicity after subunit and polymeric subunit influenza vaccines administration among...
Kostinov M. P., Cherdantsev A. P., Kuselman A. I., Akhmatova N. K., Kostinova A. M., Deryabina E. V., Demina E. O., Kostinov A. M.
Human Vaccines and Immunotherapeutics
Vol.14, Issue12, P. 2971-2978
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.1080/21645515.2018.1507585
Аннотация:
Pregnant women are risk group for influenza infection. Results of new subunit vaccines application have not been studied enough. Prospective, randomized, open-label comparative study of subunit (Agrippal) and polymeric subunit (Grippol plus) vaccines. 42 pairs of mothers-infants were participated in the study. Protective antibodies (≥ 1:40) to different influenza strains were registered on day 1 after the birth on the same level as 53[%] of cases in pairs mothers-infants after immune adjuvant polymeric subunit and subunit vaccines administration. There were the same level of protective antibodies (AB) among mothers after 3 month, but transplacental antibodies decreased among infants and registered in the 13–22[%] cases of Grippol plus group and 31–43[%] cases in Agrippal S1 group. AB titre to influenza virus A/H1N1/pdm09 and A/H3N2/in pairs mothers-infants were the same in both groups in first days after birth, but AB levels to B strain were lower among infants without regard to vaccine. The
Ключевые слова:
influenza; polymeric-subunit; pregnant women; vaccine
azoximer bromide; grippol plus; immunological adjuvant; influenza vaccine; interleukin 1beta; interleukin 6; subunit vaccine; tumor necrosis factor; virus antibody; adult; antibody titer; Article; cellular immunity; comparative study; controlled study; cytochemistry; female; follow up; gestation period; hemagglutination inhibition test; human; human experiment; humoral immunity; immune response; immunization; immunomodulation; incidence; infant; influenza; influenza A (H1N1); Influenza A virus (H1N1); Influenza A virus (H3N2); Influenzavirus A; newborn; normal human; pregnant woman; prospective study; randomized controlled trial; seroconversion; single drug dose; vaccination; vaccine immunogenicity
Язык текста: Английский
ISSN: 2164-554X
Kostinov M. P. Mikhail Petrovich 1956-
Cherdantsev A. P.
Kuselman A. I.
Akhmatova N. K.
Kostinova A. M.
Deryabina E. V.
Demina E. O.
Kostinov A. M.
Костинов М. П. Михаил Петрович 1956-
Черданцев А. П.
Куселман А. И.
Ахматова Н. К.
Костинова А. М.
Дерябина Е. В.
Демина Е. О.
Костинов А. М.
Prospective randomized open-label comparative study of immunogenicity after subunit and polymeric subunit influenza vaccines administration among mothers and infants
Prospective randomized open-label comparative study of immunogenicity after subunit and polymeric subunit influenza vaccines administration among...
Текст визуальный непосредственный
Human Vaccines and Immunotherapeutics
Vol.14, Issue12 P. 2971-2978
2018
Статья
influenza polymeric-subunit pregnant women vaccine
azoximer bromide grippol plus immunological adjuvant influenza vaccine interleukin 1beta interleukin 6 subunit vaccine tumor necrosis factor virus antibody adult antibody titer Article cellular immunity comparative study controlled study cytochemistry female follow up gestation period hemagglutination inhibition test human human experiment humoral immunity immune response immunization immunomodulation incidence infant influenza influenza A (H1N1) Influenza A virus (H1N1) Influenza A virus (H3N2) Influenzavirus A newborn normal human pregnant woman prospective study randomized controlled trial seroconversion single drug dose vaccination vaccine immunogenicity
Pregnant women are risk group for influenza infection. Results of new subunit vaccines application have not been studied enough. Prospective, randomized, open-label comparative study of subunit (Agrippal) and polymeric subunit (Grippol plus) vaccines. 42 pairs of mothers-infants were participated in the study. Protective antibodies (≥ 1:40) to different influenza strains were registered on day 1 after the birth on the same level as 53[%] of cases in pairs mothers-infants after immune adjuvant polymeric subunit and subunit vaccines administration. There were the same level of protective antibodies (AB) among mothers after 3 month, but transplacental antibodies decreased among infants and registered in the 13–22[%] cases of Grippol plus group and 31–43[%] cases in Agrippal S1 group. AB titre to influenza virus A/H1N1/pdm09 and A/H3N2/in pairs mothers-infants were the same in both groups in first days after birth, but AB levels to B strain were lower among infants without regard to vaccine. The